Abstract
Vaccines that generate Ag-specific CD8+ T-cell responses of appropriate quality, magnitude and duration are highly desirable. The ability of mTOR to regulate CD8+ T-cell functional differentiation must be exploited for clinical benefit. In a recent paper, we report that varying the regimen of rapamycin administration regulates viral vaccine-induced CD8+ T-cell responses for tumor immunity. These observations validate the use of rapamycin in vaccination strategies and demonstrate the efficacy of memory CD8+ T-cell responses for tumor immunity.
Original language | English (US) |
---|---|
Pages (from-to) | 1189-1190 |
Number of pages | 2 |
Journal | OncoImmunology |
Volume | 1 |
Issue number | 7 |
DOIs | |
State | Published - 2012 |
Keywords
- Cancer
- Memory CD8 T cells
- Rapamycin
- Vaccine
- mTOR
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology